Multifunctional Nanomedicine for Targeted Carcinoid Cancer Therapy
Researcher: Herbert Chen, MD Location: University of Wisconsin-Madison State: Wisconsin Year: 2014 Status: Finished
This grant was issued in partnership with American Association for Cancer Research
Leave it blank
To study a new anti-cancer drug with a new delivery method to target the somatostatin receptors present on neuroendocrine cancer cells. The investigators will conduct preclinical experiments to establish the feasibility of this new treatment strategy for treating patients with neuroendocrine, including carcinoid cancers.
This research project brings together a multidisciplinary team to develop a new targeted treatment strategy for neuroendocrine cancer patients, including carcinoid cancer patients. This new treatment strategy combines a new anti-cancer drug with a new delivery method to target somatostatin receptors present on neuroendocrine cancer cells.
The investigators will conduct preclinical experiments to establish the feasibility of this new treatment strategy for treating patients with neuroendocrine, including carcinoid, cancers.
Investigate whether a new anti-cancer medication, TDP-A, optimally inhibits carcinoid cancer cell proliferation and bioactive hormone secretion in vitro.
Determine if tumor-targeted TDP-A loaded multifunctional drug nanocarriers can improve carcinoid tumor uptake and anticancer efficacy while decreasing systemic toxicity.
The incidence of carcinoid tumors has increased from 3% to 10% over the past 30 years. While surgical resection can be potentially curative, many patients develop metastatic disease precluding an operative cure. Moreover, patients with carcinoid metastases often develop malignant carcinoid syndrome with the associated endocrinopathies. This emphasizes the need for the development of new forms of therapy to prevent carcinoid cancer progression and to palliate hormone associated symptoms.
This project combines the expertise of three professionals – a chemical biologist who recently discovered a new and potent anticancer drug (ie, thailandepsin A [TDP-A]), a nanotechnologist/materials chemist who develops multifunctional drug nanocarriers for targeted cancer therapy, and a surgeon/neuroendocrine cancer biologist – to develop multifunctional nanomedicines for targeted carcinoid cancer therapy. At the completion of the project, we intend to demonstrate that TDP-A is a potent anticancer drug for carcinoid cancers and that tumor-targeting TDP-A loaded nanocarriers have the potential to significantly enhance the efficacy of therapeutic treatments in carcinoid cancers while minimizing any undesirable side-effects.
NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston MA 02116